1p9t: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Theoretical Model'''
{{Theoretical_model}}


The entry 1P9T is a Theoretical Model titled 'Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs'.
==CORONAVIRUS MAIN PROTEINASE (3CLPRO) STRUCTURE: BASIS FOR DESIGN OF ANTI-SARS DRUGS==
<StructureSection load='1p9t' size='340' side='right'caption='[[1p9t]]' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1P9T FirstGlance]. <br>
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1p9t FirstGlance], [https://www.ebi.ac.uk/pdbsum/1p9t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1p9t ProSAT]</span></td></tr>
</table>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.


[[Category:Theoretical Model]]
Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.,Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R Science. 2003 Jun 13;300(5626):1763-7. Epub 2003 May 13. PMID:12746549<ref>PMID:12746549</ref>


 
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 30 09:52:35 2008''
</div>
<div class="pdbe-citations 1p9t" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Theoretical Model]]
[[Category: Large Structures]]
[[Category: Anand, K]]
[[Category: Hilgenfeld, R]]
[[Category: Mesters, J R]]
[[Category: Wadhwani, P]]
[[Category: Ziebuhr, J]]